Item 2.02. Results of Operations and Financial Condition.

In connection with the press release described in Item 8.01 below, on January 9, 2023, Rigel Pharmaceuticals, Inc. ("Rigel") provided, on a preliminary and unaudited basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2022. The preliminary estimates are based on currently available information and do not present all necessary information for a complete understanding of Rigel's financial condition as of December 31, 2022 or Rigel's results of operations for the fourth quarter or year ended December 31, 2022.




Item 8.01. Other Events.

On January 9, 2023, Rigel issued a press release titled "Rigel Pharmaceuticals Provides Business Update." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.



Exhibit                                  Description

  99.1       Press Release, dated January 9, 2023, titled "Rigel Pharmaceuticals
           Provides Business Update"

104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document)

© Edgar Online, source Glimpses